MEDICINOVA INC 8-K

What Happened
MediciNova, Inc. filed an 8-K on June 24, 2026 reporting the results of its 2026 Annual Meeting held on June 23, 2026 (proxy filed April 29, 2026). At the April 24, 2026 record date the company had 49,221,246 shares outstanding, and 29,774,819 shares were present in person or by proxy (a quorum). Two Class I director nominees—Hikedi Nagao and Nicole Lemerond—were elected to serve until the 2029 annual meeting. The selection of BDO USA, P.C. as the independent registered public accounting firm for fiscal 2026 was ratified. A proposed amendment to increase authorized common stock from 100,000,000 to 247,000,000 shares was not approved. An adjournment proposal to allow further solicitation, if needed, was approved.

Key Details

• Record date/outstanding shares: 49,221,246; shares present at meeting: 29,774,819.
• Director elections: Hikedi Nagao — For 20,910,659; Against 4,569,243; Abstain 787,267; Broker non-vote 3,507,650. Nicole Lemerond — For 21,513,456; Against 3,997,348; Abstain 756,365; Broker non-vote 3,507,650.
• Auditor ratification: BDO USA, P.C. — For 26,697,794; Against 1,911,245; Abstain 1,165,780.
• Authorized shares amendment (failed): For 22,156,922; Against 6,432,457; Abstain 1,185,440.
• Adjournment to solicit additional proxies: For 22,656,038; Against 5,805,893; Abstain 1,312,888.

Why It Matters

• The failed amendment means MediciNova’s authorized common shares remain at 100,000,000, which may limit the company’s ability to issue additional shares for financing, equity compensation or other corporate actions unless approved in the future.
• Election of directors and ratification of the auditor are routine governance outcomes that affirm current management/audit arrangements.
• Approval of the adjournment provides the company an option to solicit further votes on proposals in the future.